CARLSBAD, Calif.–(BUSINESS WIRE<\/a>)–Lineage Cell Therapeutics, Inc.<\/a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that the Company is expected to be added to the broad-market Russell 3000\u00ae<\/span><\/sup>Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective as of the U.S. market open on June 26, 2023, according to a preliminary list of additions posted to the FTSE Russell website<\/a>, following the close of the U.S. markets on May 19, 2023.<\/p>\n \nAnnual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of April 28, 2023, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000\u00ae<\/sup> Index, which remains in place for one year following reconstitution, means automatic inclusion in the large-cap Russell 1000\u00ae<\/span><\/sup> Index or small-cap Russell 2000\u00ae<\/span><\/sup> Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.<\/p>\n \n\u201cWe are pleased that Lineage is expected to be added into the Russell 3000 Index next month. Our inclusion among larger market cap companies should help to expand investor awareness, increase institutional ownership, and provide additional liquidity in our stock,\u201d stated Brian M. Culley, Lineage CEO, \u201cThis recognition of our progress comes during an exciting time, as our partners Roche and Genentech enroll patients in a Phase 2a clinical trial of OpRegen\u00ae<\/sup> for the treatment of dry age-related macular degeneration, as we prepare for further clinical testing of our OPC1 treatment for spinal cord injury, and as we advance our other treatments for cancer, hearing loss, and vision loss. Overall, we believe a deeper understanding of Lineage\u2019s strategic objectives can help increase support for our novel and exciting approach to cell transplant medicine.\u201d<\/p>\n About FTSE Russell<\/b><\/p>\n \nFTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $20.1 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information on the Russell indexes reconstitution, go to the \u201cRussell Reconstitution\u201d section on the FTSE Russell website<\/a>.<\/p>\n About Lineage Cell Therapeutics, Inc.<\/b><\/p>\n \nLineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage\u2019s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage\u2019s clinical and preclinical programs are in markets with billion dollar opportunities and include five allogeneic (\u201coff-the-shelf\u201d) product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development for the treatment of geographic atrophy secondary to age-related macular degeneration, is being developed<\/a> under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1\/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage\u2019s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit www.lineagecell.com<\/a> or follow the company on Twitter @LineageCell<\/a>.<\/p>\n Forward-Looking Statements<\/b><\/p>\n \nLineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as \u201cbelieve,\u201d \u201caim,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cdesign,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201ccould,\u201d \u201ccan,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccontemplate,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201ctend to,\u201d or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to: the expectation that Lineage will be added to the Russell 3000 Index at reconstitution and the impacts to Lineage as a result thereof; the significance of the Phase 2a clinical study of OpRegen; the timing of anticipated clinical activity related to our programs; the potential future achievements of our clinical, preclinical and development programs; our ability to broaden awareness of and increase support for our business; and the potential of our cell therapy platform. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage\u2019s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the following risks: that positive findings in early clinical and\/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and\/or nonclinical studies of that candidate; that Roche and Genentech may not successfully advance OpRegen or be successful in completing further clinical trials for OpRegen and\/or obtaining regulatory approval for OpRegen in any particular jurisdiction; that competing alternative therapies may adversely impact the commercial potential of OpRegen; that Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance with current good manufacturing practice; and those risks and uncertainties inherent in Lineage\u2019s business and other risks discussed in Lineage\u2019s filings with the Securities and Exchange Commission (SEC). Lineage\u2019s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading \u201cRisk Factors\u201d in Lineage\u2019s periodic reports with the SEC, including Lineage\u2019s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC and its other reports, which are available from the SEC\u2019s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230522005300\/en\/<\/a><\/span><\/p>\n Lineage Cell Therapeutics, Inc. IR LifeSci Advisors Russo Partners \u2013 Media Relations KEYWORDS:<\/b> California United States North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Oncology Health Infectious Diseases General Health Pharmaceutical Optical Biotechnology<\/p>\n<\/p>\n
\n<\/b>
Ioana C. Hone
\n
(ir@lineagecell.com<\/a>)
\n
(442) 287-8963<\/p>\n
\n<\/b>
Daniel Ferry
\n
(daniel@lifesciadvisors.com<\/a>)
\n
(617) 430-7576<\/p>\n
\n<\/b>
Nic Johnson or David Schull
\n
(Nic.johnson@russopartnersllc.com<\/a>)
\n
(David.schull@russopartnersllc.com<\/a>)
\n
(212) 845-4242<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20230522005300\/en\/1765407\/3\/LINEAGE_2023_RGB_JPG_1740x360.jpg\")
<\/td>\n<\/tr>\n